June 2023
Volume 64, Issue 9
Open Access
ARVO Imaging in the Eye Conference Abstract  |   June 2023
Assessment of Retinal Nerve Fiber Layer Thickness Using Optical Coherence Tomography Before and After Ranibizumab Intravitreal Injection in Patients with Diabetic Macular Edema
Author Affiliations & Notes
  • Abdelrahman M Elhusseiny
    University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
  • Amr Hassan
    South Valley University, Qena, Egypt
  • Ahmad Aldghaimy
    South Valley University, Qena, Egypt
  • Ahmed Mohalhal
    South Valley University, Qena, Egypt
  • Osama Elsoghair
    South Valley University, Qena, Egypt
  • Footnotes
    Commercial Relationships   Abdelrahman Elhusseiny, None; Amr Hassan, None; Ahmad Aldghaimy, None; Ahmed Mohalhal, None; Osama Elsoghair, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, PB0040. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Abdelrahman M Elhusseiny, Amr Hassan, Ahmad Aldghaimy, Ahmed Mohalhal, Osama Elsoghair; Assessment of Retinal Nerve Fiber Layer Thickness Using Optical Coherence Tomography Before and After Ranibizumab Intravitreal Injection in Patients with Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2023;64(9):PB0040.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the effects of anti-vascular endothelial growth factor (Anti-VEGF) injections in patients with diabetic macular edema (DME) on the retinal nerve fiber layer (RNFL) thickness.

Methods : Inclusion criteria included patients of either sex with type 2 diabetes mellitus who developed DME. Exclusion criteria included children, patients with very dense cataracts precluding visualization of the fundus or proper assessment of visual acuity, patients with other types of retinopathies, patients who had previous laser or ocular surgery, and patients with ischemia (macular or retinal) or proliferative diabetic retinopathy detected on fluorescein angiography. Fellow eyes of the included patients were used as controls. All the patients underwent spectral-domain optical coherence tomography (SD-OCT) pre-injection and once (one to four weeks) following intravitreal ranibizumab injection. These scans were marked as the patient’s baseline and were used for referencing the subsequent scans using the “follow-up” function of the SD-OCT, assuring us that the scans were performed in the same position. All images were taken as close to the optic disc as possible to ensure, to the best extent possible, that the same retinal area was being scanned.

Results : 35 (70%) patients were females, and 15 (30%) of them were males. 26 patients (52%) had their right eye injected, and 24 patients (48%) had their left eye injected. The mean age of the patients was 60±7.9 years (range = 43:75 years). The superior quadrant of the RNFL showed a mean increase of 1.2 microns (standard deviation (SD) = 38.4, 95% confidence interval (CI) = -9.7:12.1, p-value = 0.829). The inferior quadrant showed a mean increase of 7.5 microns (SD = 35.6, 95% CI = -2.6:17.6, p-value = 0.144). The nasal quadrant showed a mean increase of 8.3 microns (SD = 23, 95% CI = 1.8:14.9, p-value = 0.014). The temporal quadrant showed a mean increase of 4.1 microns (SD = 33.2, 95% CI = -5.3:13.6, p-value = 0.386).

Conclusions : There is no statistically significant correlation between intravitreal injections of ranibizumab and the RNFL thickness.

This abstract was presented at the 2023 ARVO Imaging in the Eye Conference, held in New Orleans, LA, April 21-22, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×